Oncoinvent AS, a clinical stage radiopharmaceutical company, announces that its CEO, Jan A. Alfheim will present the company at DNB’s 13th annual Nordic Healthcare Conference 2022 on 15th of December 2022. The presentation will take place from 09:50-10:10 CET in the Market Session Room C2.
Oncoinvent AS Gullhaugveien 7 0484 Oslo Norway
mansson@oncoinvent.com
+47 488 68 863
Anders Månsson is a business executive with over 25 years of experience from management roles in the pharmaceutical industry, focusing on commercialisation and M&A + licensing. Mr. Månsson has held leading roles in the industry both in his native Sweden and in other European countries, and he has worked extensively with the USA and Asia as focus markets in global roles.
Mr. Månsson holds a B.Sc. degree in Business & Economics from Lund’s University in Sweden as well as an MBA from Business School Lausanne in Switzerland. He has a broad-based industrial experience, featuring both large multinational companies such as Meda, Ferring & LEO Pharma, and including leading roles in start-ups and smaller biotech companies. On top of his executive role in Oncoinvent, Mr. Månsson holds two non-executive director positions serving on the board of EQL Pharma AB as well Immetric AB, the latter being an investment company focusing on life science.